Iovance Biotherapeutics Inc (IOVA) reaches revenue targets and plans global expansion, despite facing competition and ...

Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.

Iovance Biotherapeutics, Inc. sees mixed TIL therapy success with Amtagvi in PD-1-refractory melanoma. Click here to find out ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) was the recipient of some unusual options trading on Friday. Stock traders purchased 20,884 call options on the company. This is an ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) today and set a price ...

Iovance Biotherapeutics, Inc.’s IOVA share price has dipped by 19.49%, which has investors questioning if this is right time ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Iovance Biotherapeutics (IOVA – Research ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.38, a high estimate of $32.00, and a low estimate of $6.00. Highlighting a 10.88% decrease, the current ...

New York State Common Retirement Fund trimmed its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free ...

Iovance Biotherapeutics shares dip 18% despite strong Q4 results due to concerns over inflation, geopolitical risks, and operational challenges. Read more here.

The commercial-stage biotechnology company posted revenue of $73.7 million for the quarter, missing the consensus estimate of $77.33 million. However, adjusted earnings per share came in at -$0.26, ...